NCT07100119View on ClinicalTrials.gov

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

September 30, 2027

Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
DRUG

LY4256984

Administered IT

DRUG

Placebo

Administered IT

Trial Locations (10)

3000

UZ Leuven, Leuven

3584

Universitair Medisch Centrum Utrecht, Utrecht

18147

"Universitätsmedizin Rostock Sektion für Translationale Neurodegeneration Albrecht Kossel Klinik und Poliklinik für Neurologie", Rostock

23538

Universitätsklinikum Schleswig-Holstein, Lübeck

46026

Hospital Universitari i Politecnic La Fe, Valencia

89081

Universitätsklinikum Ulm, Ulm

T2N4Z6

Heritage Medical Research Clinic, Calgary

M4N 3M5

Sunnybrook Research Institute, Toronto

H3A 2B4

Montreal Neurological Institute and Hospital, Montreal

08907

Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY